Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
DSGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.15 - $7.77
Previous CloseN/A
Volume97.34K
Average Volume (3M)156.72K
Market Cap
$204.63M
Enterprise Value$53.07M
Total Cash (Recent Filing)$29.40M
Total Debt (Recent Filing)$2.88M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
May 12, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding56,762,676
10 Day Avg. Volume99,588
30 Day Avg. Volume156,718
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$5.00Price Target Upside31.93% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Design Therapeutics News
PremiumCompany Announcements
Design Therapeutics Updates Corporate Presentation for Investors
PremiumCompany Announcements
Design Therapeutics Reports Strong Q3 and Pipeline Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsDSGN is on track to initiate the Phase 1 single ascending dose study in healthy volunteers and to initiate FA patient dosing.
Drug DevelopmentDSGN's new formulation, DT-216P2, has demonstrated an improved PK profile, an improved injection site safety profile, and more sustained drug exposure in preclinical models compared to the prior formulation.
Bears Say
Financial PerformanceDSGN reported a net loss of $11.8M or $(0.21) per share for 2Q24.
---
Ownership Overview
19.58% Insiders
6.66% Mutual Funds
30.69% Other Institutional Investors
37.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $3.15 and its highest was $7.77 in the past 12 months.
What is Design Therapeutics’s market cap?
Design Therapeutics’s market cap is $204.63M.
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 38 days.
How were Design Therapeutics’s earnings last quarter?
Design Therapeutics released its earnings results on Mar 10, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.027.
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 56,762,676 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Design Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -1.016%.
Which hedge fund is a major shareholder of Design Therapeutics?
Currently, no hedge funds are holding shares in DSGN
---
Design Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (31.93% Upside)
$5.00 (31.93% Upside)
Hedge Fund Trend
Increased
By 776.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.86%
12-Months-Change
Fundamentals
Return on Equity
-19.08%
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
---
DSGN Stock 12 Month Forecast
Average Price Target
$5.00
▲(31.93% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Foghorn Therapeutics
―
Best Analysts Covering DSGN
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-50.19%
upgraded a buy rating 11 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -50.19% per trade.
---